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Introduction
Implantation of an intraocular lens (IOL) at the time of cataract surgery is commonly done 
for most patients above one year of age. (1) There is considerably less consensus on the 
proper role of IOL implantation in infants. (2–7) Theoretical advantages of primary IOL 
implantation at the time of cataract surgery in infants include having a constant, albeit 
partial, optical correction during the early years of visual development, the ability to place 
the IOL within the capsular bag and the avoidance of contact lens use with the associated 
cost and effort required of the child’s caregivers. (8, 9) Advantages of leaving the baby 
aphakic and visually rehabilitating the eye with a contact lens include the ability to change 
the contact lens power as needed to keep up with the rapidly growing eye’s refractive needs, 
not subjecting the baby to the increased rate of complications and subsequent need for 
additional surgeries associated with IOL implantation and not requiring spectacle wear 
during the first few years of life. (10–18)
The Infant Aphakic Treatment study is a multicenter, randomized clinical trial that compares 
the use of primary IOL implantation with spectacle correction of residual hyperopia to the 
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correction of aphakia with a contact lens after cataract surgery performed in infants with a 
unilateral congenital cataract between 1 and 7 months of age. (19) The study found no 
significant difference in grating visual acuity between the two groups at one year of age, but 
there was a significantly higher rate of complications, adverse events and need for additional 
intraocular surgeries in the IOL group at that time. (4) The optotype visual acuities obtained 
at 4.5 years in the IATS were recently reported. (20) Consistent with the one year grating 
acuities, the 4.5 year optotype acuities showed no significant difference between the two 
study groups.
The purpose of this report is to examine in greater depth the rate and character of adverse 
events and additional intraocular surgeries required by age five years. This analysis will 
hopefully assist in formulating recommendations for the use of IOL implantation in infants.
Methods
The study design (multi-center randomized clinical trial), surgical techniques, follow up 
schedule and patient characteristics at baseline, as well as the clinical findings at one year of 
age have been reported in detail previously and are only summarized here. (4, 19) This study 
was approved by the Institutional Review Boards of all 12 participating institutions and was 
in compliance with the Health Insurance Portability and Accountability Act. Informed 
consent was obtained from all parents or guardians. The off-label research use of the 
Acrysof SN60AT and MA60AC IOLs (Alcon Laboratories, Fort Worth, Texas) was covered 
by US Food and Drug Administration investigational device exemption # G020021. The 
trial is registered at www.clincaltrials.gov (Identifier- NCT00212134).
Study Design
The main inclusion criteria were a visually significant congenital cataract (> 3 mm central 
opacity) in one eye and an age of 28 days to <210 days at the time of cataract surgery. 
Infants with a unilateral cataract due to persistent fetal vasculature were allowed in the study 
as long as the persistent fetal vasculature was not associated with visible stretching of the 
ciliary processes or involvement of the retina or optic nerve.
Infants randomized to the contact lens group underwent a lensectomy and anterior 
vitrectomy. Infants randomized to the IOL group had the lens contents aspirated followed by 
the implantation of an AcrySof SN60AT IOL into the capsular bag. In the event that both 
haptics could not be implanted into the capsular bag, an AcrySof MA60AC IOL was 
implanted into the ciliary sulcus. The IOL power was calculated based on the Holladay 1 
formula targeting a postoperative refractive error of +8 D for infants 4–6 weeks of age and 
+6 D for infants older than 6 weeks. Following IOL placement, a posterior capsulectomy 
and an anterior vitrectomy were performed through the pars plana/plicata. When either a 
pre-existing opening was present, as sometimes occurs with posterior lenticonus defects, or 
a rent developed intraoperatively in the posterior capsule and in some eyes with mild PFV, 
the posterior capsulectomy and anterior vitrectomy were performed through the anterior 
incision prior to IOL implantation.
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There were 114 children enrolled in the study with 57 randomized to each treatment group. 
In years 2–5 following surgery, the patients were examined by an Infant Aphakia Treatment 
Study certified investigator every 3 months until 4 ½ years of age and then a final exam at 
age 5 years. One hundred and thirteen patients had a clinical exam at age 5 years (mean, 5.0 
years; range, 4.7 – 5.4 years) with an average length of follow-up of 4.8 years (range, 4.4 – 
5.3 years) after cataract surgery. One patient in the IOL group was lost to follow-up at age 
18 months.
Adverse Events
IOP was measured using rebound tonometry (ICare Finland, Helsinki, Finland), a Tonopen 
(Reichert Technologies, Depew, NY) or Goldmann applanation tonometry.
Glaucoma was defined as IOP >21 mmHg with one or more of the following anatomical 
changes: 1) corneal enlargement; 2) asymmetrical progressive myopic shift coupled with 
enlargement of the corneal diameter and/or axial length; 3) increased optic nerve cupping 
defined as an increase of ≥ 0.2 in the cup-to-disc ratio, or 4) the use of a surgical procedure 
to lower IOP.
Glaucoma suspect was defined as either: 1) two consecutive IOP measurements above 21 
mmHg on different dates after topical corticosteroids had been discontinued without any of 
the anatomical changes listed above; or 2) glaucoma medications were used to control IOP 
without any of the anatomical changes listed above.
A corneal ulcer was defined as a corneal epithelial defect with an associated corneal 
infiltrate whereas a corneal abrasion was defined as a corneal epithelial defect with no 
infiltrate.
Lens reproliferation into the visual axis was defined as lens regrowth extending into the 
pupillary space and interfering with vision. Other adverse events encountered that were 
deemed to not require definition include: pupillary membrane, corectopia, vitreous 
hemorrhage, hyphema, retained cortex, retinal detachment, corneal edema, wound leak, IOL 
capture, endophthalmitis and phthisis bulbi.
Statistical Methods
The percentage of patients experiencing one or more adverse events was compared between 
the treatment groups using Fisher’s exact test. The analysis was done for the first year 
following cataract surgery, for the follow-up period after the first year and over the entire 
follow-up period. The same approach was used to compare the percentage of patients 
undergoing one or more additional ocular surgical procedures. The rate for the number of 
adverse events per patient-year of follow-up was compared between the treatment groups 
using the exact binomial test for comparing two Poisson means. This analysis was done for 
the first postoperative year and for the follow-up period after the first year. This same 
method was also used to compare the rate of ocular surgery procedures per patient-year of 
follow-up.
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Results
Adverse Events
Table 1 shows the adverse events that occurred in each treatment group during the first year 
after cataract surgery as previously reported (11) as well as those that occurred in years 2 
thru 5 of follow-up.
During the first year after cataract surgery a lower percentage of contact lens patients 
experienced one or more adverse events compared to IOL patients (contact lens: 15 (26%), 
IOL: 44 (77%), p < 0.0001). After the first year there was a trend for a higher percentage of 
contact lens patients to experience an adverse event (contact lens: 24 (42%), IOL: 14 (25%), 
p = 0.073). Over the entire follow-up period, the proportion of contact lens patients 
experiencing an adverse event was lower than the IOL patients (contact lens: 32 (56%), IOL: 
46 (81%), p = 0.008.
Table 1 further shows the number of patients who had at least one adverse event. For the 
majority, there was one event per patient. The exceptions are the following: In the contact 
lens group there were 4 contact lens related adverse events among 3 patients in the first year 
and 14 events among 7 patients after the first year for a total of 18 events among 10 patients. 
In the IOL group, during the first year, there were multiple instances of the following 
adverse events: lens reproliferation – 27 among 23 patients; pupillary membrane – 20 among 
16 patients; corectopia – 15 among 13 patients; and retained cortex – 4 among 3 patients. 
After the first year: pupillary membrane – 5 among 3 patients and hyphema – 2 in 1 patient.
During the first year, in the contact lens group there were 22 adverse events among 15 
patients and in the IOL group there were 88 events among 44 patients. When translated to an 
annual rate, the number of adverse events per year of follow-up was significantly lower in 
the contact lens group compared to the IOL group (contact lens: 0.4, IOL: 1.6, p < 0.0001). 
After the first year, there were 33 events among 24 patients in the contact lens group and 21 
events among 14 patients in the IOL group, which yielded rates that were not significantly 
different in the two groups (contact lens: 0.2, IOL: 0.1, p = 0.15).
Compared to the first postoperative year in which there was a total of 110 adverse events 
(contact lens: 22, IOL: 88), there were only 54 adverse events (contact lens: 33, IOL: 21) in 
years 2–5. A large majority of the adverse events during the five years of follow up in the 
IOL group occurred in the first year (88 of 108, 81%). Conversely, more adverse events in 
the contact lens group developed in years 2–5 than occurred in the first year (33 of 54, 61%).
Thirty of the 33 adverse events that developed in the contact lens group in years 2–5 were 
glaucoma related (n=16) or contact lens related (n=14). Seventeen of the 21 adverse events 
that developed in the IOL group in years 2–5 were visual axis related (n=10) or glaucoma 
related (n=7).
Additional Intra-ocular surgeries
As shown in Table 2, there were more patients with unplanned intraocular procedures in the 
IOL group (n=8) than the contact lens group (n=4) during post-operative years 2–5.
Plager et al. Page 4
Am J Ophthalmol. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
IOL group- 8 patients had procedures to clear visual axis opacities, 2 had glaucoma 
surgery and 2 had an IOL exchange
Contact lens group- 3 patients had procedures to clear visual axis opacities and 1 had 
glaucoma surgery.
In addition, 3 patients in the contact lens group underwent elective secondary IOL 
implant because of their inability to wear a contact lens successfully.
During the first year after cataract surgery a lower percentage of contact lens patients had 
one or more additional surgical procedures compared to IOL patients (contact lens: 7 (12%), 
IOL: 36 (63%), p < 0.0001). After the first year the percentage of patients having surgery 
did not differ significantly between the groups (contact lens: 4 (7%), IOL: 8 (14%), p = 
0.36). Over the entire follow-up period, a lower percentage of contact lens patients had 
additional intraocular surgery (contact lens: 9 (16%), IOL: 41 (72%), p < 0.0001).
For most of the procedures listed in Table 2, there was one procedure per patient. The 
exceptions are the following: In the contact lens group, during the first year there were 8 
procedures involving clearing visual axis opacities among 6 patients and 3 procedures for 
repairing a retinal detachment among 2 patients. In the IOL group, during the first year, 
there were 44 procedures involving clearing visual axis opacities among 34 patients and 
after the first year there were 10 similar procedures among 8 patients.
During the first year, in the contact lens group there were 13 surgical procedures among 7 
patients and in the IOL group there were 52 procedures among 36 patients. The 
corresponding rate of procedures per year was significantly lower in the contact lens group 
(contact lens: 0.2, IOL: 0.9, p < 0.0001). After the first year, there were 4 procedures among 
4 patients in the contact lens group and 14 procedures among 8 patients in the IOL group, 
resulting in a lower rate in the contact lens group (contact lens: 0.02, IOL: 0.07, p = 0.029). 
As with the first year procedures, the most common unplanned additional intraocular 
procedure was done to clear visual axis opacity (contact lens group, n=3 (75%); IOL group, 
n=10 (71%)). Of the total of five other intraocular procedures, 3 were for glaucoma (IOL 
group, n=2) and 2 were IOL exchanges.
Discussion
As previously reported, at one year of age the patients in the IOL group had experienced 
more intraoperative complications (28% vs. 11%, p=.031), postoperative adverse events 
(77% vs 25%, p< .0001) and required more additional intraocular surgeries (63% vs 12%, 
p< .0001) than did babies who were left aphakic. (11) The most common adverse event was 
visual axis opacification and the most common additional intraocular surgery was a clearing 
of visual axis opacification.
The numbers of adverse events that developed in years 2–5 of follow-up were relatively few 
(n=54) compared to the first postoperative year (n=110). Nearly half of the 54 adverse 
events (n=23) were related to glaucoma. Ten patients were diagnosed with glaucoma and 13 
became glaucoma suspects during years 2–5. This was in addition to 10 patients who had 
been diagnosed with glaucoma during the first year. At five years, a total of 20 children in 
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the contact lens group had been diagnosed with glaucoma or labeled a glaucoma suspect 
versus a total of 16 children in the IOL group, an insignificant difference. The expectation is 
that the numbers of children diagnosed with glaucoma will continue to rise with time. 
Glaucoma is probably the most important long term issue facing patients who undergo 
cataract surgery in the first six months of life (this topic will be covered in more detail in a 
subsequent publication from this study).
Another area where we can expect to see the numbers of adverse events rise with time will 
be contact lens related events. There were 4 such events in the first year and 14 in the 
subsequent four years. As long as children continue to wear contact lenses, more contact 
lens related adverse events are likely to occur. Fortunately, to date, none of the contact lens 
related events, which include two corneal ulcers, have resulted in loss of vision.
In the IOL group, 3 patients to date have undergone IOL exchange because of an excessive 
myopic shift. It can be expected that this number may rise over the next decade of continued 
growth of these young eyes with associated change in refractive error.
Only one eye of the 114 eyes in the study lost vision completely (NLP). This was a patient 
in the contact lens group that developed a retinal detachment in the early postoperative 
period and the eye became phthisical. A second child, also in the contact lens group, 
developed endophthalmitis in the early postoperative period and had only LP vision at 4.5 
years.
Ultimately, the clinician treating infants with congenital cataracts would like to know if 
implantation of an IOL at the time of cataract surgery is advisable. While there is no clear-
cut answer for all patients, the data favor delaying IOL implantation until the child is older 
for families that can reasonably manage contact lens care and expense. Delaying IOL 
implantation until later years after most of the growth in axial length has occurred also 
obviates some of the unpredictability in selecting an appropriate IOL power for 
implantation.
However for other families, for whom contact lens care may be burdensome, the answer is 
not so clear. While there is no advantage in the visual outcome at age 4.5 years if an IOL is 
implanted (20), there are other advantages to primary IOL implantation. The most obvious 
to the families involved is that it is not necessary for the baby to wear a contact lens. The 
extent to which this is an advantage will differ among patients and families. Some caregivers 
can become quite adept at handling the contact lens and some babies adapt to them well, but 
obviating this chore would likely be welcomed by most. In some family situations, the effort 
required to successfully wear an aphakic contact lens in a young child presents an 
insurmountable barrier. Additionally, the cost associated with many years of contact lens 
wear, especially in cases where the lens is frequently lost, is a significant burden. Notably, 
the financial barrier to contact lens wear was removed for the families in the Infant Aphakia 
Treatment Study because all associated contact lens expenses were borne by the study.
Another, at least theoretic, advantage to primary IOL implantation is that the IOL can be 
more reliably placed within the capsular bag at the time of the original surgery than as a 
secondary procedure (21). Although the long term risk of placing an IOL in the sulcus of a 
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baby in terms of future IOL decentration or uveitis related complications is unknown, it is 
likely that capsular bag fixation will be more secure and less prone to adverse events over 
the long life span of these babies.
These real and potential advantages need to be weighed against the higher rate of 
complications, adverse events and need for additional intraocular surgeries associated with 
primary IOL placement in infancy. At five years of age, the total number of additional 
unplanned intraocular surgeries clearly favor the contact lens group – there were 66 
procedures in the IOL group versus 17 in the CL contact lens group. However it is important 
to realize that the two groups are not equivalent- the contact lens group is aphakic and the 
IOL patients are pseudophakic. Many of children in the aphakic group will opt to have a 
secondary IOL electively placed in future years and these secondary implant procedures 
may themselves be associated with additional complications. On the other hand, an 
unknown number of children in the pseudophakic group will likely opt for an IOL exchange 
to manage unacceptably high myopic refractive errors that develop with future axial length 
growth. In sum, these anticipated additional intraocular surgeries will likely bring the total 
number of surgeries for the two groups closer together.
The aphakic patients in the Infant Aphakia Treatment Study were discouraged from having a 
secondary IOL implanted during the five years of the study, but despite extensive efforts by 
study investigators and coordinators to sustain contact lens wear in all patients, three 
patients were declared contact lens failures and a secondary IOL was implanted prior to five 
years of age. In the pseudophakic group, a similar effort was made to sustain spectacle wear 
for residual refractive error. Despite this effort, three patients who developed highly myopic 
refractive errors as the axial length of the eye increased underwent IOL exchange prior to 
five years of age.
Another area besides contact lens and glasses compliance where the results found in this 
study may be difficult to duplicate in the real world is in the numbers of complications, 
adverse events and additional intraocular surgeries. The numbers of these in this study were 
significant, but they may represent a best case scenario. All surgeons participating in the 
study were highly experienced pediatric cataract/IOL surgeons. All were required to submit 
surgical videos before they were certified to participate that documented their ability to 
perform the surgical procedures mandated by the study protocol on infants similar to the 
ones to be enrolled in the study. It is possible that the complication rate of surgeons less 
experienced with the particular challenges of cataract/IOL surgery on infant eyes would be 
even higher than that encountered in this study.
In conclusion, compared to infants with no IOL, patients treated with primary IOL 
implantation prior to 7 months of age had more adverse events and required more additional 
intraocular surgeries over the first five years following surgery for unilateral congenital 
cataract, with most occurring during the first postoperative year. While there was no visual 
benefit demonstrated at 5 years of age and an increased risk of adverse events and additional 
intraocular surgeries associated with primary IOL implantation in early infancy, there are 
other factors that could influence the decision whether to implant an IOL in a particular 
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baby. We suggest that surgeons continue to exercise caution when considering IOL 
implantation in the management of congenital cataract in the first 7 months of life.
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